GlaxoSmithKline Pharmaceuticals Limited has filed its quarterly compliance certificate with the Bombay Stock Exchange (BSE) and National Stock Exchange (NSE) for the quarter ended March 31, 2026. The submission fulfills the company's regulatory obligations under SEBI (Depositories and Participants) Regulations, 2018.

Regulatory Compliance Filing

The pharmaceutical company submitted the certificate on April 9, 2026, in compliance with Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. The document was signed by Ajay Nadkarni, Vice President – Administration, Real Estate & Company Secretary, confirming the company's adherence to mandatory reporting requirements.

Certificate Details

The compliance certificate was issued by Kfin Technologies Limited, which serves as the company's Registrar and Share Transfer Agent. The certificate covers the dematerialisation activities for the quarter ended March 31, 2026.

Dematerialisation Compliance

Kfin Technologies Limited confirmed that all securities received from depository participants for dematerialisation during the quarter were properly processed. The registrar verified that:

• Securities received for dematerialisation were confirmed to depositories
• All securities were listed on stock exchanges where earlier issued securities are listed
• Security certificates received for dematerialisation were mutilated and cancelled after verification
• Depository names were substituted in the register of members as registered owners within the stipulated 30-day period

Corporate Information

The certificate was signed by Dnyanesh Gharote, Vice President at Kfin Technologies Limited. GlaxoSmithKline Pharmaceuticals Limited operates from its registered office at GSK House, Dr. Annie Besant Road, Worli, Mumbai, with CIN L24239MH1924PLC001151.

This routine compliance filing demonstrates the company's commitment to maintaining transparency and adhering to SEBI regulations governing depositories and share transfer processes.

GlaxoSmithKline Pharmaceuticals Limited has successfully completed its postal ballot process, with shareholders decisively approving the appointment of Mr. Ronojit Biswas in dual leadership roles. The company announced the results on April 8, 2026, following the conclusion of the electronic voting period.

Postal Ballot Results Overview

The pharmaceutical company conducted the postal ballot process through remote e-voting for two ordinary resolutions related to Mr. Ronojit Biswas's appointments. The voting period commenced on March 9, 2026, at 09:00 a.m. and concluded on April 8, 2026, at 05:00 p.m.

Resolution 1: Director Appointment

The first resolution for appointing Mr. Ronojit Biswas (DIN: 07684843) as Director received overwhelming support from shareholders across all categories.

Resolution 2: CFO Appointment

The second resolution for appointing Mr. Ronojit Biswas as Whole-time Director & Chief Financial Officer demonstrated even stronger support from shareholders.

Scrutinizer Report Highlights

P.N. Parikh of Parikh & Associates, serving as the appointed scrutinizer, confirmed the validity of the voting process. The scrutinizer's report detailed the comprehensive e-voting procedure conducted through KFintech's platform.

Corporate Governance Compliance

The postal ballot process was conducted in full compliance with Section 110 of the Companies Act, 2013, and the Companies (Management and Administration) Rules, 2014. The company also adhered to Regulation 44(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The voting results and scrutinizer's report have been made available on the company's website and KFintech's e-voting platform, ensuring transparency in the corporate governance process. With these appointments approved, Mr. Ronojit Biswas will assume his roles as Director and Chief Financial Officer, contributing to the company's leadership structure.